Bayer has advanced its small-molecule drug BAY 2927088 into phase 3 for non-small cell lung cancer (NSCLC) with HER2 activating mutations, one of the drugs central to the company’s plan to ...
Bayer announced initiation of a phase I clinical trial with ... tolerability and preliminary efficacy of BAY3498264 as a combination therapy in patients with advanced KRAS G12C-mutated solid tumours.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback